Literature DB >> 23470070

RETIRED: Current status in non-invasive prenatal detection of Down syndrome, trisomy 18, and trisomy 13 using cell-free DNA in maternal plasma.

Sylvie Langlois1, Jo-Ann Brock2.   

Abstract

This document has been archived because it contains outdated information. It should not be consulted for clinical use, but for historical research only. Please visit the journal website for the most recent guidelines.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23470070     DOI： 10.1016/S1701-2163(15)31025-2

Source DB:  PubMed          Journal:  J Obstet Gynaecol Can        ISSN： 1701-2163


  21 in total

1.  Not-so-free testing for cell-free DNA.

Authors:  Darryl Huang; Karen Lundgard; Michael R Kolber
Journal:  Can Fam Physician       Date:  2016-10       Impact factor: 3.275

2.  The Integration of Noninvasive Prenatal Screening into the Existing Prenatal Paradigm: a Survey of Current Genetic Counseling Practice.

Authors:  Emily Suskin; Laura Hercher; Kathleen Erskine Aaron; Komal Bajaj
Journal:  J Genet Couns       Date:  2016-02-15       Impact factor: 2.537

Review 3.  Integration of noninvasive DNA testing for aneuploidy into prenatal care: what has happened since the rubber met the road?

Authors:  Diana W Bianchi; Louise Wilkins-Haug
Journal:  Clin Chem       Date:  2013-11-19       Impact factor: 8.327

4.  Selected birth defects data from population-based birth defects surveillance programs in the United States, 2006 to 2010: featuring trisomy conditions.

Authors:  Cara T Mai; James E Kucik; Jennifer Isenburg; Marcia L Feldkamp; Lisa K Marengo; Erin M Bugenske; Phoebe G Thorpe; Jodi M Jackson; Adolfo Correa; Russel Rickard; C J Alverson; Russell S Kirby
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2013-11

5.  Expanding diagnostic testing beyond cytogenetics: implications for birth defects research and surveillance.

Authors:  Jodi M Jackson; Charlotte M Druschel; Stuart K Shapira
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2013-11-06

6.  Survey of the Definition of Fetal Viability and the Availability, Indications, and Decision Making Processes for Post-Viability Termination of Pregnancy for Fetal Abnormalities and Health Conditions in Canada.

Authors:  Danna Hull; Gregory Davies; Christine M Armour
Journal:  J Genet Couns       Date:  2015-11-05       Impact factor: 2.537

7.  Incorporation of dried blood alpha fetoprotein into traditional first trimester Down syndrome screening service.

Authors:  Jonathan Carmichael; David Krantz; Hsiao-Pin Liu; David Janik; Terrence Hallahan
Journal:  Prenat Diagn       Date:  2015-05-13       Impact factor: 3.050

8.  Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service.

Authors:  Stephen Morris; Saffron Karlsen; Nancy Chung; Melissa Hill; Lyn S Chitty
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

Review 9.  Non-Invasive Prenatal Testing Using Cell Free DNA in Maternal Plasma: Recent Developments and Future Prospects.

Authors:  Peter Benn
Journal:  J Clin Med       Date:  2014-05-21       Impact factor: 4.241

Review 10.  Counseling Challenges with Variants of Uncertain Significance and Incidental Findings in Prenatal Genetic Screening and Diagnosis.

Authors:  Lauren Westerfield; Sandra Darilek; Ignatia B van den Veyver
Journal:  J Clin Med       Date:  2014-09-12       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.